D-Leucine
CAS RN: 328-38-1
| Solubility in 3M-HCl | Colorless & clear (c=5) |
| Specific rotation [α]D20 | -14.8°~-15.7°(c=4, 6M-HCl) |
| Loss on drying | Not more than 0.3% |
| Residue on ignition (as sulfate) | Not more than 0.1% |
| Chloride (Cl) | Not more than 0.02% |
| Sulfate (SO4) | Not more than 0.03% |
| Heavy metals (as Pb) | Not more than 10ppm |
| Iron (Fe) | Not more than 10ppm |
| Ammonium (NH4) | Not more than 0.02% |
| Arsenic (As2O3) | Not more than 1ppm |
| Other amino acids | Not detected by T.L.C.(The spotted amount, 50μg) |
| Assay | 98.5%～101.0% |
| L-Isomer | Not more than 0.5% |
We are professional D-Leucineleucine; manufacturer and (2R)-2-amino-4-methylpentanoic acid supplier in China, We offer quality (R)-2-Amino-4-methylpentanoic acid you can fully trust, also we have India factory and producer of D-Leucine,Pls send inquiry of D-Leucine CAS:328-38-1 to info@nbinno.com if you have any interests, thank you!
Related News: If an API is not ultrapure, a medicine cannot meet the strict quality criteria so the quality of an API plays a very important role.3-Fluoroanisole CAS:456-49-5 At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.Methyl 2-(2-(((benzyloxy)carbonyl)amino)thiazol-4-yl)acetate At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth.4-Hydroxyphenyl hydantoin CAS:2420-17-9 Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.In addition, due to the complex process of changing the API supplier and the risk of uncertainty, the viscosity of pharmaceutical and specialty API companies is usually better.
